Nektar Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BMV:NKTR * Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
19 Feb 25	SellMex$490,963	Howard Robin	Individual	23,774	Mex$20.65
19 Feb 25	SellMex$227,990	Mark Wilson	Individual	11,040	Mex$20.65
19 Feb 25	SellMex$212,708	Jonathan Zalevsky	Individual	10,300	Mex$20.65
24 Dec 24	SellMex$297,602	Mark Wilson	Individual	16,560	Mex$17.97
23 Dec 24	SellMex$606,879	Mark Wilson	Individual	33,402	Mex$18.17
19 Dec 24	SellMex$982,761	Jonathan Zalevsky	Individual	51,115	Mex$19.23
18 Dec 24	SellMex$2,655,307	Howard Robin	Individual	132,030	Mex$20.37
19 Nov 24	SellMex$130,694	Mark Wilson	Individual	6,407	Mex$20.40
19 Nov 24	SellMex$158,804	Jonathan Zalevsky	Individual	7,785	Mex$20.40
19 Nov 24	SellMex$332,050	Howard Robin	Individual	16,278	Mex$20.40
19 Aug 24	SellMex$356,708	Howard Robin	Individual	14,881	Mex$23.97
19 Aug 24	SellMex$135,458	Mark Wilson	Individual	5,651	Mex$23.97
19 Aug 24	SellMex$164,583	Jonathan Zalevsky	Individual	6,866	Mex$23.97

Insider Trading Volume

Insider Buying: NKTR * insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of NKTR *?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	2,445,443	1.31%
General Public	59,196,756	31.8%
Institutions	124,461,389	66.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 54.36% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
8.44%	BlackRock, Inc.	15,707,325	Mex$209.5m	-2.39%	no data
6.61%	The Vanguard Group, Inc.	12,309,688	Mex$164.2m	-0.15%	no data
4.19%	Nantahala Capital Management, LLC	7,789,051	Mex$103.9m	-0.27%	0.41%
3.87%	Acadian Asset Management LLC	7,201,089	Mex$96.1m	0%	0.01%
3.57%	Eventide Asset Management, LLC	6,650,000	Mex$88.7m	0%	0.09%
2.88%	PRIMECAP Management Company	5,354,586	Mex$71.4m	-3.35%	no data
2.53%	Renaissance Technologies LLC	4,701,781	Mex$62.7m	20.2%	no data
2.48%	Almitas Capital LLC	4,610,872	Mex$61.5m	401%	0.64%
2.15%	Geode Capital Management, LLC	4,009,124	Mex$53.5m	1.3%	no data
2.15%	TCG Crossover Management, LLC	4,000,000	Mex$53.4m	0%	0.37%
1.98%	Woodline Partners LP	3,691,878	Mex$49.2m	-25.8%	0.02%
1.75%	State Street Global Advisors, Inc.	3,258,290	Mex$43.5m	-0.42%	no data
1.62%	Jacobs Levy Equity Management Inc	3,007,928	Mex$40.1m	14.5%	0.01%
1.23%	Millennium Management LLC	2,288,802	Mex$30.5m	-49.4%	no data
1.2%	Exome Asset Management LLC	2,232,453	Mex$29.8m	261%	1.38%
1.18%	22NW, LP	2,191,750	Mex$29.2m	0%	0.96%
0.89%	Mackenzie Financial Corporation	1,658,745	Mex$22.1m	253%	no data
0.85%	Ikarian Capital, LLC	1,579,528	Mex$21.1m	-22.2%	0.39%
0.77%	Two Sigma Investments, LP	1,435,096	Mex$19.1m	-6.65%	no data
0.77%	Charles Schwab Investment Management, Inc.	1,434,457	Mex$19.1m	-2.16%	no data
0.76%	Two Sigma Advisers, LP	1,420,542	Mex$18.9m	-4.42%	no data
0.76%	Northern Trust Global Investments	1,417,166	Mex$18.9m	0.15%	no data
0.59%	Union Square Park Capital Management, LLC	1,100,000	Mex$14.7m	0%	0.75%
0.57%	Monaco Asset Management S.A.M.	1,068,899	Mex$14.3m	-47.4%	0.37%
0.56%	Altium Capital Management LP	1,051,379	Mex$14.0m	-65%	2.1%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/18 01:23
End of Day Share Price	2025/02/28 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nektar Therapeutics is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Richard Silver	Barclays
Aydin Huseynov	Benchmark Company
George Farmer	BMO Capital Markets Equity Research